Nivolumab subcutaneous administration (Revolka)

纳武利尤单抗皮下注射剂 (Revolka)

Report date: 2025/04/07 14:32:47

Base Information

Drug NameNivolumab subcutaneous administration (Revolka)
Drug Alias NameRK-001
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 inhibitors
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesRevolKa Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRevolKa Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A